Can-Fite BioPharma (NYSE:CANF) Trading 5.4% Higher

Can-Fite BioPharma Ltd. (NYSE:CANF) shot up 5.4% during mid-day trading on Wednesday . The stock traded as high as $2.43 and last traded at $2.34. 111,037 shares changed hands during mid-day trading, an increase of 96% from the average session volume of 56,560 shares. The stock had previously closed at $2.22.

Analyst Ratings Changes

CANF has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Thursday, May 9th. EF Hutton Acquisition Co. I raised Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th. Finally, StockNews.com started coverage on Can-Fite BioPharma in a research report on Friday, July 19th. They issued a “hold” rating on the stock.

Can-Fite BioPharma Stock Down 4.2 %

The business’s fifty day moving average price is $2.82 and its 200 day moving average price is $2.48. The firm has a market capitalization of $7.89 million, a PE ratio of -1.25 and a beta of 1.41.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Armistice Capital LLC bought a new position in Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 154,363 shares of the company’s stock, valued at approximately $340,000. Armistice Capital LLC owned about 4.36% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.